BPH Global Ltd

BP8 to Expand Seaweed R&D Activities into Essential Mineral Extraction Utilising AI Search Technology; Carbon Credits

The Board of BPH Global Ltd (ASX: BP8) (Company) is pleased to announce that the Company is expanding the nature of its business to include the following projects:

  • Essential mineral extraction: The Company’s extraction of individual macro minerals and micro minerals from seaweed and sea plant biomass, to enable the sale of those macro and micro minerals to the commodities markets, and to industry specific markets such as the battery industry, and thereby create an additional revenue stream for the Company; and
  • Seaweed and Blue Carbon Credits: The Company’s sale of seaweed cellulose fibre as a filler in biopolymer, bioplastic and battery electrolyte solution separator materials as revenue streams for the Company and to serve as a means of evidencing carbon sequestration and storage for the purposes of qualifying for blue carbon credits. On receipt of the blue carbon credits, the Company would seek to sell those blue carbon credits as an additional revenue stream. (Together, the New Projects)
  • R&D program now includes:
    • Essential Mineral Extraction: extraction of seaweed-based individual macro & micro minerals for sale into the commodities markets and industry specific markets like the battery and energy industries;
    • Artificial Intelligence technology (AI): AI to be developed and deployed to enhance nutraceutical and essential mineral identification and extraction; and
    • Carbon Credits: sale of seaweed cellulose fibre to the building materials and battery industries to attract Carbon Credits.
  • R&D program focussed on potential commercialisation opportunities.
The research and development (R&D) that the Company intends to undertake on the New Projects is in addition to the Company’s existing R&D activity which is focusses on:
  • Edible bird’s nest product enhancement by the infusion of seaweed-derived nutrients; and
  • Creation of a range of prototypes for food products, dietary supplements, healthcare products, and cosmetic applications that incorporate seaweed-sourced and/or bird’s nest-sourced nutraceuticals.

ASX Listing Rule 11.1.2 doesn’t apply to the expanded “nature” of the Company’s business

Following its review of the Company’s submission letter, the Company has received notice from ASX that the expenditure of $250,000 to investigate the possibilities of the New Projects will not attract the application of Listing Rules 11.1.2. The Company will notify ASX once anything eventuates from the R&D on the New Projects, and if the Company decides to pursue further opportunities, to report to ASX on the size and scope of the further developments.

Essential Mineral Extraction

Seaweed in general has a chemical composition significant in polysaccharides (agar), essential minerals and trace elements, although the composition varies from species to species. The target compounds of interest to the Company will affect the choice of species selection for the sake of commercial production and will also affect the method of post-harvest treatment and extraction for specific compounds.

For essential mineral extraction for sale into the commodities markets and for use in the battery technology and energy production industries, the initial specific focus is on nickel and cobalt. The Company is also monitoring the results of published research regarding the use of seaweed-derived chemicals and cellulose micromaterials in enhancing battery performance. Examples of recently published studies include the improvement made by added cellulose micromaterials to battery separators in sodium-metal batteries and to a prototype battery electrode made from a combination of silicon and a seaweed-derived alginate which improved the electrode’s elasticity and ability to store energy. The Company regards itself as a potential supplier of essential minerals, including these seaweed-derived cellulose micromaterials and alginates, to the current and emerging battery technology and battery manufacturing industries.

Regarding essential mineral extraction for use in vitamin supplement manufacture, the Company’s specific focus is on trace metals that are established by science to occur in rich concentrations in seaweed: nickel, cobalt and manganese. These minerals are common trace elements in vitamin supplements.

Click here for the full ASX Release

This article includes content from BPH Global Ltd, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.

The Conversation (0)
Genes and chromosomes with "2024" overlay.

Biotech Market Update: Q1 2024 in Review

The first quarter of 2024 witnessed a surge in initial public offerings (IPOs) and mergers and acquisitions (M&A) within the biotech industry, signaling continued interest from investors.

AstraZeneca’s acquisition of start-up Amolyt on March 14, and its longtime biotech partner Fusion Pharmaceuticals for US$2.4 billion on March 19 marked the third acquisition of a radiopharmaceutical developer in recent months. As of writing, there have been 14 M&A deals struck in 2024, according to data from Biopharma Dive.

Investment bank Jefferies released data in early March revealing that the sector was on track to earn its highest quarterly total in three years, reflecting the cautiously optimistic outlook at this year's JPM24 conference.

Keep reading...Show less


Planning Underway for Phase 3 Development of Tezepelumab in COPD

Amgen (NASDAQ:AMGN) today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE ® (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD), which were accepted for presentation in the Clinical Trials Symposium at The American Thoracic Society (ATS) 2024 International Conference on Monday, May 20 from 9:15-11:15 a.m. PDT .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Close up 3D rendering of DNA strands.

Biotech Stocks: 5 Biggest Companies in 2024

What are the top biotech companies? The following five stocks have market capitalizations worth billions of dollars and operate in countries all around the globe.

Plus, these big-name biotech players have pipelines stuffed with potentially disruptive products — and enough revenue to recover should some of those products fail.

This means that investors can experience the excitement of biotech investing while minimizing risk. Although returns are never guaranteed, company size can insulate investors from volatility.

Keep reading...Show less
SIRONA BIOCHEM Corporate Update April 2024

SIRONA BIOCHEM Corporate Update April 2024

Sirona Biochem Corp . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona " or the " Company ") provides the following update:

Dear shareholders,

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Sirona Biochem Announces Close of Private Placement

Sirona Biochem Announces Close of Private Placement

Vancouver, British Columbia – April 4, 2024 Sirona Biochem Corp . (TSX-V: SBM) (Frankfurt: ZSB) (" Sirona ") has closed its private placement (Private Placement") for gross proceeds of $132,500 CAD. The Private Placement consists of 1,325,000 units, (the "Units") at a price of $0.10 per Unit. Each Unit consists of one common share and one transferable share purchase warrant, each whole warrant exercisable into one additional common share of the Company for a period of 2 years from the date of issue at a price of $0.15 per Share in year one and $0.25 per Share in year two. All securities issued under the Private Placement are subject to statutory hold periods expiring on August 4, 2024.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Need injecting into red and white cell.

How to Invest in Biotechnology (Updated 2024)

Investors interested in the life science sector are well aware of the importance of biotechnology.

From finding cures for diseases to feeding future generations, many areas of day-to-day life are influenced by players in the biotechnology space, and expert projections show the industry's future looks bright.

But how can investors gain exposure to biotechnology? Here’s a brief overview of how to invest in the expanding biotechnology market, from stocks to watch to exchange-traded funds (ETFs).

Keep reading...Show less

Latest Press Releases

Related News